AGIOS PHARMACEUTICALS
Agios Pharmaceuticals is a biopharmaceutical company, discovers and develops therapeutics in the field of cancer metabolism. It also develops drugs that focus on glycolysis, fatty acid metabolism, and autophagy. The company's therapeutics are used in the areas of autoimmune, inflammatory, and neurological diseases. Agios Pharmaceuticals was formerly known as CANCER METABOLISM THERAPEUTICS And changed its name to Agios Pharmaceuticals In April 2008. The company is based in Cambridge, Massachusetts.
AGIOS PHARMACEUTICALS
Industry:
Biotechnology Health Care Medical Pharmaceutical
Founded:
2008-01-01
Address:
Cambridge, Massachusetts, United States
Country:
United States
Website Url:
http://www.agios.com
Total Employee:
101+
Status:
Active
Contact:
+1 617 649 8600
Email Addresses:
[email protected]
Total Funding:
775.82 M USD
Technology used in webpage:
Apple Mobile Web Clips Icon HSTS IPv6 ReCAPTCHA Cloudflare Hosting ReCAPTCHA V2 Microsoft HSTS IncludeSubdomains PreLoad Ruby On Rails Token DigiCert SSL
Similar Organizations
Alnylam Pharmaceuticals
Alnylam Pharmaceuticals is a biopharmaceutical company focused on the discovery, development and commercialization.
AVEO Oncology
AVEO is a biopharmaceutical company that offers drug development strategies for targeted cancer therapeutics.
Celator Pharmaceuticals
Celator Pharmaceuticals is a biopharmaceutical company developing therapies to treat cancer, using the drug ratio technology platform.
CStone Pharmaceuticals
CStone Pharmaceuticals is a bio-pharmaceutical company develops new treatments in a range of therapeutic areas.
Fovea Pharmaceuticals
Fovea Pharmaceuticals is a French biopharmaceutical company that discovers and develops drugs for the treatment of ocular diseases.
PIQUR Therapeutics
PIQUR Therapeutics is a Swiss pharmaceutical company focusing on the discovery and development of anti-cancer drugs.
Quest PharmaTech
Quest PharmaTech is a pharmaceutical company that is developing antibody-based immunotherapeutic products for cancer.
Trevarx Biomedical
Trevarx Biomedical is a biomedical startup that develops new radiopharmaceuticals.
Vion Pharmaceuticals Inc
Vion Pharmaceuticals, Inc. is a biopharmaceutical company that discovers, develops, and commercializes cancer treatment technologies.
Current Advisors List
Current Employees Featured
Founder
Stock Details
Investors List
Celgene
Celgene investment in Series C - Agios Pharmaceuticals
Flagship Pioneering
Flagship Pioneering investment in Series C - Agios Pharmaceuticals
ARCH Venture Partners
ARCH Venture Partners investment in Series C - Agios Pharmaceuticals
Third Rock Ventures
Third Rock Ventures investment in Series C - Agios Pharmaceuticals
Celgene
Celgene investment in Series B - Agios Pharmaceuticals
Flagship Pioneering
Flagship Pioneering investment in Series A - Agios Pharmaceuticals
ARCH Venture Partners
ARCH Venture Partners investment in Series A - Agios Pharmaceuticals
Third Rock Ventures
Third Rock Ventures investment in Series A - Agios Pharmaceuticals
Key Employee Changes
| Date | New article |
|---|---|
| 2022-12-06 | Agios Appoints Tsveta Milanova as Chief Commercial Officer |
| 2022-07-13 | Agios appoints Brian Goff as new CEO |
Official Site Inspections
http://www.agios.com Semrush global rank: 2.93 M Semrush visits lastest month: 5.44 K
- Host name: 83.162.211.130.bc.googleusercontent.com
- IP address: 130.211.162.83
- Location: Mountain View United States
- Latitude: 37.4043
- Longitude: -122.0748
- Metro Code: 807
- Timezone: America/Los_Angeles
- Postal: 94043
More informations about "Agios Pharmaceuticals"
About Us - Agios
Across our business, and beyond the walls of our organization, we foster connections that drive results and impact for patients. We share a set of values that promote contribution, …See details»
Inside Agios – Agios
As an organization that values and embraces differences, we’re continuously looking to improve the inclusivity of our workforce. This commitment is essential to our success and helps drive our ability to create transformative medicines …See details»
Agios Pharmaceuticals - LinkedIn
Agios Pharmaceuticals | 80,574 followers on LinkedIn. ... RDN, president of the Thrive with Pyruvate Kinase Deficiency Organization, who shares practical tips on nutrition, advice on supplements ...See details»
Agios Pharmaceuticals - Wikipedia
Agios Pharmaceuticals Inc. is a publicly trading American pharmaceutical company pioneering therapies for genetically defined diseases, with a near-term focus on developing therapies for hemolytic anemias. The company was founded in 2008 (or 2007) by Lewis Cantley, Tak Mak and Craig Thompson. Agios is a Delaware corporation headquartered in Cambridge, Massachusetts. The c…See details»
Growing Together…Development @ Agios - LinkedIn
Sep 20, 2017 Agios has scaled rapidly over the past 2+ years – growing from 100 people to more than 350 strong. One of our biggest priorities as a team is how to evolve and grow the company AND maintain the ...See details»
Agios Announces Evolution of Research Organization
May 16, 2022 Agios plans to reduce up to 50 roles focused on exploratory research, while retaining a strong internal research team focused on roles critical to advancing the company’s …See details»
Agios Publishes 2024 Environmental, Social and Governance (ESG) …
CAMBRIDGE, Mass., April 09, 2024 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in cellular metabolism and PK activation pioneering therapies for …See details»
Leadership - Agios
At Agios, leadership means building stronger bonds with colleagues, partners and patient communities and honoring each of their perspectives to make the process of developing life-changing treatments for patients with rare diseases more …See details»
Agios Announces Evolution of Research Organization
May 16, 2022 Agios plans to reduce up to 50 roles focused on exploratory research, while retaining a strong internal research team focused on roles critical to advancing the company’s …See details»
Agios Pharmaceuticals - Crunchbase Company Profile …
Agios Pharmaceuticals is a biopharmaceutical company, discovers and develops therapeutics in the field of cancer metabolism. It also develops drugs that focus on glycolysis, fatty acid metabolism, and autophagy. The company's …See details»
Servier to Acquire Agios Pharmaceuticals’ Oncology Business
Organization's skill sets are recognized and leveraged for the benefit of patients. With our commercial expertise, global reach, scientific expertise and commitment to clinical excellence, …See details»
Agios Reports Business Highlights and Third Quarter 2024 …
Oct 31, 2024 Agios is the pioneering leader in PK activation and is dedicated to developing and delivering transformative therapies for patients living with rare diseases. In the U.S. , Agios …See details»
Agios Reports Fourth Quarter and Full Year 2023 Financial Results …
CAMBRIDGE, Mass., Feb. 15, 2024 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in the field of cellular metabolism pioneering therapies for rare …See details»
Culture – Agios
At Agios, this deep sense of caring is what drives every person on our team and enables us to do meaningful work on behalf of people with rare diseases. It is central to our people …See details»
Servier completes acquisition of Agios’ oncology business
On April 1 st , 2021, Servier announced the successful acquisition of Agios Pharmaceuticals’ commercial, clinical, and research-stage oncology portfolio.This acquisition immediately …See details»
Agios Highlights 2021 Milestones to Accelerate and Expand Its ...
Jan 11, 2021 Such forward-looking statements include those regarding Agios’ plans, strategies and expectations for the preclinical, clinical and commercial advancement of its drug …See details»
Values – Agios
At Agios, we are committed to making the world a better place, being a good neighbor in our communities, and conducting business ethically, responsibly and transparently. ... As an …See details»
Is Agios Pharmaceuticals (AGIO) Stock Outpacing Its Medical Peers …
3 days ago Agios Pharmaceuticals is currently sporting a Zacks Rank of #2 (Buy). Within the past quarter, the Zacks Consensus Estimate for AGIO's full-year earnings has moved 90.7% …See details»
Investors Overview – Agios Pharmaceuticals, Inc.
Nov 5, 2024 Agios is a biopharmaceutical company that is fueled by connections. The strong bonds we build with patient communities, partners and colleagues enrich the impact we have …See details»
Diversity – Agios
At Agios, our approach to diversity, equity and inclusion (DE&I) is guided by our Valuing Differences framework. This framework helps drive our culture and innovative spirit. It …See details»